Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke

Launched by EMMANUEL CARRERA · Jul 14, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a medicine called Maraviroc can help improve movement and motor skills in people who have had a recent ischemic stroke, which is a type of stroke caused by a blockage in blood flow to the brain. The study will compare Maraviroc to a placebo (a harmless, inactive pill) to see if it helps patients recover better use of their arms and hands during the first three months after their stroke.

People who might be eligible to join this study are adults who have had an ischemic stroke within the last 7 days and have some weakness in one arm or hand, but still have some ability to move their fingers. Participants must be 18 years or older and able to give informed consent. The trial will not include people who are pregnant, have severe pre-existing disabilities, certain other neurological diseases, or serious liver or kidney problems. If you join, you can expect to receive either Maraviroc or a placebo without knowing which one, and doctors will closely monitor your motor skills and recovery. This trial is not yet recruiting but aims to find new ways to help stroke survivors regain better movement.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Informed consent as documented by signature
• • ≥18 years at time of signing of informed consent
• • Acute ischemic stroke.
• • Stroke onset \< 7 days from randomization.
• * Contralateral, unilateral, incomplete upper limb paresis, incl. :
• • FMA-UE \< 63/66
• • Residual voluntary finger extension (VFE) of \> 10 degrees
• Exclusion Criteria:
• • Pregnancy/lactation or positive pregnancy test in women of childbearing age
• • Pre-stroke handicap (mRS \> 2)
• • Diseases affecting motor function (e.g., Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS))
• • Participation in another study with investigational medicinal product within 30 days preceding and during the present study
• • Enrolment of the investigator, his/her family members, employees, or other dependent persons
• • Known hypersensitivity to Maraviroc, Mannitol, peanuts, or soy
• • History of significant liver disease, hepatitis, elevated liver function tests (\> 1.5 upper limit of normal)
• • History of significant renal disease or End Stage Renal Disease/dialysis, acute renal injury, Creatinine Clearance (CrCl \< 30ml/min/1.73m2)
• • Patients with cardiovascular comorbidities and risk for orthostatic hypotension
• • HIV infection
• • Concomitant use of strong CYP3A4 inhibitors or inducers